ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

Date: Saturday, November 6, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM
Abstract Number: 0354
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0325
A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0341
Addition of Narrative Text Abstraction to ICD-Based Abstraction Significantly Improves Identification of Lupus Nephritis in Real-World Data
8:30AM-10:30AM
Abstract Number: 0344
Anti-gAChR Antibody as a Novel Biomarker for Lupus Enteritis in Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0345
Anti-MPP-1 Autoantibodies in Systemic Lupus Erythematosus: A Potential Biomarker for Neuropsychiatric Manifestations
8:30AM-10:30AM
Abstract Number: 0326
Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations
8:30AM-10:30AM
Abstract Number: 0334
Association Between Systemic Lupus Erythematosus and Myasthenia Gravis: A Population-Based National Study
8:30AM-10:30AM
Abstract Number: 0350
EPI-SIGN: Epigenetic SLE Indicators of Glomerular Nephritis
8:30AM-10:30AM
Abstract Number: 0351
Gene Signature Fingerprints Divide SLE Patients in Subgroups with Similar Biological Disease Profiles: A Multicenter Longitudinal Study
8:30AM-10:30AM
Abstract Number: 0327
Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency
8:30AM-10:30AM
Abstract Number: 0347
Longitudinal ANA Titers in SLE and ANA+ Controls
8:30AM-10:30AM
Abstract Number: 0324
Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World
8:30AM-10:30AM
Abstract Number: 0352
Native American and African American Rheumatic Disease Patients Exhibit Accelerated Biological Aging Compared to European Americans
8:30AM-10:30AM
Abstract Number: 0328
Natural Language Processing to Identify Lupus Nephritis Phenotype in Electronic Health Records
8:30AM-10:30AM
Abstract Number: 0343
Overview of the Childhood Systemic Lupus Erythematosus (cSLE) Cohort in the CARRA Registry
8:30AM-10:30AM
Abstract Number: 0349
Performance of the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Predominantly African American Cohort
8:30AM-10:30AM
Abstract Number: 0335
Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey
8:30AM-10:30AM
Abstract Number: 0332
Prevalence of Systemic Lupus Erythematosus in the United States: Updated Population Representative Estimates from the Medical Expenditure Panel Survey (MEPS) 2016-2018
8:30AM-10:30AM
Abstract Number: 0329
Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE Diagnosis in a Multi-Ethnic Cohort
8:30AM-10:30AM
Abstract Number: 0342
RAIL Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 0337
Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record
8:30AM-10:30AM
Abstract Number: 0323
Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients
8:30AM-10:30AM
Abstract Number: 0330
Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
8:30AM-10:30AM
Abstract Number: 0338
Serum and Urine Galectin-9, IP-10 and SIGLEC-1 as Biomarkers of Disease Activity in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0353
Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 0346
The CB-CAPillaryTM Test Kit: A Tool for Point-of-Care Assays to Measure Cell-Bound Complement Activation Products
8:30AM-10:30AM
Abstract Number: 0336
The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE
8:30AM-10:30AM
Abstract Number: 0348
The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term Outcomes
8:30AM-10:30AM
Abstract Number: 0356
The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease
8:30AM-10:30AM
Abstract Number: 0339
Trends in Disparity by Age, Sex and Race for Systemic Lupus Erythematosus Patients
8:30AM-10:30AM
Abstract Number: 0340
Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
8:30AM-10:30AM
Abstract Number: 0331
Urinary MicroRNAs as Systemic Lupus Erythematosus Biomarkers and Its Potential for Accurate Assessment of Disease Severity
8:30AM-10:30AM
Abstract Number: 0355
Utilization of a Clinical Data Research Network to Assess Systemic Lupus International Collaborating Clinics Classification Criteria Attributes in Patients with Systemic Lupus Erythematosus
8:30AM-10:30AM
Abstract Number: 0333
Validation of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria for Systemic Lupus Erythematosus (SLE) in Hong Kong Chinese

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology